US/UK/Canada

Share

Links

Pick a time period -
Tags ( Active)

Synartro reports positive phase 1/2a data for SYN321

Synartro AB announced positive data from its completed Phase 1/2a clinical trial evaluating SYN321, with preliminary efficacy signals supporting further clinical development.Synartro is developing SYN321, a locally administered investigational therapy for the treatment of symptomatic OA. The phase 1/2a clinical trial focused on safety, tolerability, PK, and early efficacy signals and was concluded during the first quarter of 2026. Available data indicate that SYN321 was generally well tolerated across all evaluated dose levels, with no unexpected safety findings or dose-limiting

Synartro reports last participant’s last visit (LPLV) in phase 1/2a clinical study of OA drug candidate SYN321

Uppsala, Sweden, February 18, 2026 - Synartro announces that the final study participant has completed the final follow-up visit in the phase 1/2a clinical trial of knee osteoarthritis drug candidate SYN321.Synartro is advancing the candidate drug SYN321, a novel intra-articular treatment for knee osteoarthritis, through a phase 1/2a clinical trial focused on safety, tolerability, PK, and early efficacy signals. The study was initiated in August 2025 and a total of 35 participants with knee osteoarthritis have participated. All four cohorts were recruited and treated within a four-month

No serious adverse events to date in ongoing phase 1/2a clinical study of SYN321

Clinical study updateSynartro is advancing the candidate drug SYN321, a novel intra-articular treatment for knee osteoarthritis, through a phase 1/2a clinical study focused on safety, tolerability, PK, and early efficacy signals. The study was initiated in August 2025 following approval from the Swedish Medical Products Agency (MPA) and the Swedish Ethical Review Authority. The study has enrolled a total of 35 participants with knee osteoarthritis. All four cohorts were recruited and treated within a four-month period: Cohort 1 (n=7), Cohort 2 (n=8), Cohort 3 (n=8), and Cohort 4 (n=12).

Synartro – completed treatment of all four cohorts in phase 1/2a clinical study of SYN321

Synartro AB announces that it has completed the treatment of all four cohorts in its phase 1/2a clinical study of SYN321.Synartro is advancing the candidate drug SYN321, a novel intra-articular treatment for knee osteoarthritis, through a phase 1/2a clinical trial focused on safety, tolerability, PK, and early efficacy signals. The trial began on September 1st, 2025, and is being carried out in partnership with CTC at Uppsala University Hospital, with study completion anticipated in the spring of 2026. Following evaluation by the study’s internal safety review committee, the highest dose

Synartro - dosing of second cohort completed in clinical study of SYN321

Synartro AB announces that it has completed the treatment of the second out of four participant cohorts in its phase 1/2a clinical study of SYN321. The third cohort is to be dosed within the coming weeks.Synartro’s investigational drug SYN321 is a novel joint injection treatment targeting symptoms of knee osteoarthritis. The purpose of the ongoing phase 1/2a study is to evaluate safety and tolerability, as well as to obtain exploratory efficacy data. The first study participant was dosed on September 1st, 2025 and the study is expected to be completed in the spring of 2026. It is conducted

Synartro completes dosing of first cohort in clinical study of SYN321

Synartro AB announces that it has completed the treatment of the first out of four participant cohorts in its phase 1/2a clinical study of SYN321. The second cohort is expected to be dosed within the coming weeks.Synartro’s investigational drug SYN321 is a novel joint injection treatment targeting symptoms of knee osteoarthritis. The purpose of the ongoing phase 1/2a study is to evaluate safety and tolerability, as well as to obtain exploratory efficacy data. The first study participant was dosed on September 1st, 2025 and the study is expected to be completed in the spring of 2026. It is

Synartro has been granted regulatory and ethical approval for the first clinical trial of lead compound SYN321 for treatment of symptomatic knee osteoarthritis

Synartro announces that the company has been granted approval from the Swedish Medical Products Agency and the Swedish Ethical Review Authority to start the phase 1/2a first-in-human clinical study of the investigational drug candidate SYN321.The objective of the clinical study is to evaluate safety and tolerability, systemic exposure, and preliminary efficacy of SYN321 in patients with symptomatic knee osteoarthritis (OA). The phase 1/2a study will be conducted by Clinical Trial Consultants AB in Uppsala and is planned to start turn of the year 2023/2024. The lead candidate SYN321 is a

Synartro prepares for first clinical trial of lead compound SYN321 for treatment of symptomatic knee osteoarthritis

Synartro announced today that the company has submitted a clinical trial application to the Swedish Medical Products Agency and the Swedish Ethical Review Authority, for a phase 1/2a first-in-human clinical study of investigational drug candidate SYN321.The objective of the clinical study is to evaluate safety and tolerability, systemic exposure and preliminary efficacy of SYN321 in patients with symptomatic knee osteoarthritis (OA). The phase 1/2a study will be conducted by Clinical Trial Consultants AB in Uppsala and is planned to start during 2023. The lead candidate SYN321 is a joint

Synartro granted European patent

Synartro’s patent application for its drug delivery platform has been granted by the European Patent Office. The patent strengthens the position of the company’s lead candidate SYN321, which is developed for treatment of knee osteoarthritis. The granted patent also protects further development within other areas and indications based on the platform.The patent (European Patent No. 3226905) covers the company’s mechanism for linking hyaluronan with another active substance, as well as the method to produce the linking mechanism. With the patent, Synartro is given exclusivity in Europe until

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media